P&T MEETING AGENDA: JANUARY 20, 2026

COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING
NOTE: This special-called meeting will be held virtually via Microsoft Teams webinar.
Tuesday, January 20, 2026
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In by Phone
Microsoft Teams **Join the meeting now** Meeting ID: 269 897 502 335 07 Passcode: Vi3KQ9Gm **Download Teams | Join on the web**	+1 858-252-2734 (United States) Phone conference ID: 170 464 566#

AGENDA

I. Call to Order and Welcome

II. Executive Session (Upon Request)

III. Old Business

a. Approval of July 2025 Meeting Minutes
b. Approval of October 2025 Meeting Minutes
c. Review of Commissioner's Decision, Laxatives and Cathartics Class

IV. New Business

a. New Products to Market to be Reviewed as Single Products
   i. Brinsupri™ (Non-PDL)
   ii. Orlynvah™ (Non-PDL)
   iii. Dawnzera™ (Non-PDL)
   iv. Leqembi IQLIK™ (Central Nervous System – Alzheimer's Agents)
   v. Wayrilz™ (Blood Modifiers – Thrombopoiesis Stimulating Proteins)
   vi. Blujepa (Non-PDL)
   vii. Rhapsido® (Non-PDL)
   viii. Jascayd® (Non-PDL)
   ix. Exxua™ (Non-PDL)
   x. Lynkuet® (Non-PDL)

V. Therapeutic Classes with Recommended Changes

a. Bronchodilators, Beta-Agonist
b. Glucocorticoids, Inhaled
c. Intranasal Rhinitis Agents
d. Macrolides/Ketolides

Copyright © 2025. MedImpact Healthcare Systems, Inc.
All rights reserved.

e. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
f. Immunosuppressives, Oral

VI. Consent Agenda

a. The following therapeutic classes have no recommended changes and may be voted on as a group under a consent agenda

• Antiretrovirals, HIV/AIDS • Antibiotics, Gastrointestinal • Antibiotics, Inhaled • Antibiotics, Vaginal • Antifungals, Oral • Antihistamines, Minimally Sedating • Cephalosporins and Related Antibiotics • Epinephrine, Self-Injectable • Hepatitis B Agents • Hepatitis C Agents • Leukotriene Modifiers	• Oral Antivirals, COVID-19 • Oral Antivirals, Herpes • Oral Antivirals, Influenza • Oxazolidinones • Penicillins • Quinolones • Chronic Obstructive Pulmonary Disease (COPD) Agents • Sulfonamides, Folate Antagonist • Tetracyclines

VII. Adjournment

a. Schedule of Upcoming Meetings
   i. April 2026
   ii. July 2026
   iii. October 2026

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to https://kyportal.medimpact.com/provider-documents/drug-information.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at https://kyportal.medimpact.com/provider-documents/pt-committee.

Copyright © 2025. MedImpact Healthcare Systems, Inc.
All rights reserved.